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Abstract
Background: In March 2007, a regulatory advisory was issued in Japan to restrict oseltamivir use in children aged 10-19
years because of safety concerns over abnormal behavior. The effectiveness and validity of regulatory risk minimization
actions remain to be reviewed, despite their significant public health implications. To assess the impact of the regulatory
actions on prescribing practices and safety reporting.
Methodoloy/Prinicpal Findings: In this retrospective review of a nationwide pharmacy database, we analyzed 100,344
dispensation records for oseltamivir and zanamivir for the period from November 2006 to March 2009. The time trend in
dispensations for these antiviral agents was presented before and after the regulatory actions, contrasted with intensity of
media coverage and the numbers of spontaneous adverse reaction reports with regard to antivirals. The 2007 regulatory
actions, together with its intense media coverage, reduced oseltamivir dispensation in targeted patients in fiscal year 2008
to 20.4% of that in fiscal year 2006, although influenza activities were comparable between these fiscal years. In contrast,
zanamivir dispensation increased approximately nine-fold across all age groups. The number of abnormal behavior reports
associated with oseltamivir in children aged 10-19 years decreased from fiscal year 2006 to 2008 (24 to 9 cases); this decline
was offset by the increased number of reports of abnormal behavior in children under age 10 (12 to 28 cases). The number
of reports associated with zanamivir increased in proportion to increased dispensation of this drug (11 to 114 cases).
Conclusions/Significance: The 2007 actions effectively reduced oseltamivir prescriptions and the number of reports of
abnormal behavior in the targeted group. The observed increase in abnormal behavior reports in oseltamivir patients under
age 10 and in zanamivir patients suggests that these patient groups may also be at risk, calling into question the validity of
the current discrimination by age and agent (Abstract translation is available in Japanese: Appendix S1).
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Introduction
The neuraminidase inhibitors oseltamivir and zanamivir are the
most frequently used antivirals in the treatment of influenza. Both
have been proved effective in the treatment and prevention of
influenza, with good tolerability from children to elderly adults [1,2].
Following the launch of oseltamivir on January 2001, Japan
accounted for 75% of global consumption, or 34 million patients as
of March 2007 [3]. However, post-marketing experience raised
public and regulatory concerns over the safety profile of this drug [4];
two reported cases of falls associated with abnormal behavior in
teenagers using oseltamivir eventually triggered regulatory actions in
March 2007, namely a Dear Doctor Letter (DDL)and package insert
(PI) revision recommending against oseltamivir use in children aged
10–19 years. The Ministry of Health, Welfare and Labour (MHLW)
took this decision based on the precautionary principlewithout ample
demonstration of causality of abnormal behavior [5].
In contrast, with regard to zanamivir, a drug in the same class as
oseltamivir, the only change in the PI has been the addition of
possible neuropsychiatric symptoms in the section titled ‘‘important
precautions’’ made in January 2008 [6]. The oseltamivir-associated
risk of neuropsychiatric disorders has been controversial [7,8], and
no other regulatory agency has taken such definitive countermea-
sures to date [9,10].Moreover, the effectiveness and validityof these
2007 regulatory actions remain to be reviewed, despite their
significant public health implications.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28483Here, to assess the effectiveness of the 2007 regulatory actions in
minimizing risk of oseltamivir-associated abnormal behaviors, we
examined drug dispensation records sourced from nationwide
pharmacy chains as an index of trends in the use of antivirals for
influenza treatment in the Japanese prescribing community, and
media coverage of these antivirals. We also reviewed the national
database of spontaneous adverse reaction reports in relation to
these drugs.
Methods
Data collection
This study is a time-trend study of antiviral drug utilization
using a nationwide pharmacy claim database. The database
consisted of claim and dispensation records obtained from the
largest and third largest pharmacy chains in Japan (Ain
Pharmaciez Inc. and Kraft Inc.), which incorporated the
electronic records of prescriptions filled at 433 community
pharmacies located around Japan. The database contains data
on approximately 10 million outpatient prescriptions per year in
total, accounting for approximately 1.4% of total yearly outpatient
prescriptions in Japan [11], corresponding to a total patient
coverage of approximately 5.5 million. The age distribution of
patients in the database is well matched to national patient
statistics [12]. These two pharmacy chains primarily cover the
most-populated middle and eastern areas of Japan, from Kansai to
Hokkaido, with only minor representation in southwest Japan,
including the Chugoku, Shikoku, and Kyushu areas.
Dispensations of oseltamivir or zanamivir were examined to
investigate the impact of regulatory actions on prescribing trends.
Amantadines were excluded, owing to their infrequent use for
influenza in Japan. We studied drug dispensation records for the
prescriptions written between November 1, 2006, and March 31,
2009, a period which incorporated the DDL and subsequent PI
revision of oseltamivir, dated March 20, 2007. De-identified
dispensation records included an anonymized patient identifier,
age, gender, name, and code of the medical institution, specialty,
code of the dispensing pharmacy, date of prescription, code and
brand name of the drug, dosing days, and dosage. Antiviral
prescriptions with a dosage frequency of twice a day or more for
therapeutic purposes were eligible for analysis. Prescriptions with a
‘‘once a day’’ dosage for prevention and those with missing dosage
information were excluded from analysis. A single dispensation
record for either oseltamivir, zanamivir or both were counted as a
single episode of influenza unless antiviral dispensing was repeated
within the next five days under the same patient identifier. When
there were consecutive dispensation records of antivirals within
five days for the same patient, total dosing days of a single
treatment course for a single influenza case were calculated by
combining these records on the basis that the standard dosing
practice for the treatment of influenza is five days [13,14].
Weekly influenza activity is reported by the National Epidemi-
ological Surveillance of Infectious Diseases (NESID) based on
surveillance of approximately 5,000 sentinel hospitals and clinics
throughout Japan [15]. We used the mean incidences of clinical
influenza per sentinel site as an index of weekly influenza activity
at the national level for analysis.
Media coverage of oseltamivir and zanamivir was evaluated
using the G-Search database (G-Search Limited) [16]. The
database was searched for articles containing the keywords
‘‘Tamiflu’’ or ‘‘Oseltamivir,’’ and ‘‘Relenza’’ or ‘‘Zanamivir’’ in
the four major national and eight major regional newspapers in
Japan during the study period. The number of articles per month
was counted separately for oseltamivir and zanamivir.
Regulatory reporting on suspected adverse reactions associated
with oseltamivir and zanamivir were identified in the national
database for spontaneous case reports of suspected adverse
reaction reported to the Pharmaceuticals and Medical Devices
Agency (PMDA) [17]. Each report in the PMDA database
contains an event term reported by the healthcare professional, the
suspected drug’s name, the reporter’s opinion on causality with the
suspected drug, outcome of the event, the fiscal year of the report,
and patient’s age decile. Reported events are coded in accordance
with the Medical Dictionary for Regulatory Activities coding
system, and summarized by a Lower Level Term and a System
Organ Class [18].
Ethics
Because the pharmacy claim data investigated in the present
study were retrieved from the automated electronic database and
de-identified before provision to the study group, the study was
exempt from obtaining informed consent from individual patients
according to the local ethical guideline for epidemiological
research. This study and the waiver of informed consent were
approved by the Kyoto University Graduate School and Faculty of
Medicine, Ethics Committee (No. E-775).
Statistical analysis
Our analyses are descriptive in nature. The number of influenza
cases treated with oseltamivir or zanamivir (or both) was
aggregated for intervals appropriate for the intended analyses.
To validate the reliability of drug dispensation data as represen-
tative of national medication trends in influenza treatment, the
number of cases treated with oseltamivir or zanamivir weekly was
correlated using the Pearson correlation coefficient with weekly
national influenza activity reported by the NESID. The impact of
the regulatory actions and media coverage about antivirals on
prescribing trends of oseltamivir and zanamivir were evaluated
using the monthly or yearly number of dispensations stratified by
age groups with a 10-year interval. The numbers of yearly
dispensations were summarized for each fiscal year starting on
April 1 and ending on the following March 31 because of the
following reasons: the yearly number of dispensed cases was
compared before and after the regulatory actions taken at the end
of March 2007, which coincided with the end of fiscal year 2006.
Further, the PMDA spontaneous reporting database only includes
data of fiscal year when each case was reported, not the actual
onset date; therefore, these cases were summarized by the fiscal
year of reports, to be contrasted with the annual antiviral
dispensations. However, the number of dispensed cases for fiscal
year 2006 was calculated from records between November 1,
2006, and March 31, 2007, due to limited data availability of
pharmacy records. Thus, the reporting year may not necessarily
reflect the actual year when the event occurred. The indices for
yearly trends of adverse reaction reporting were calculated by
dividing the yearly numbers of spontaneous case reports by the
numbers of influenza cases dispensed each antiviral at the study
pharmacies. A chi-square test for independence was used with a
two-tailed significance level of 0.05. Statistical analyses were
performed with SPSS 18 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
Between November 1, 2006, and March 31, 2009, a total
100,344 dispensation records for oseltamivir and zanamivir were
analyzed. The 1,015 dispensation records for prevention or with
missing dosage were excluded from analysis. After eliminating
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97,954 influenza cases (males, 50.8%) treated with the antivirals, of
which 77,695 (males, 51.1%) were treated with oseltamivir, with a
median age of 15 years (range, 0–102); and 20,382 cases (males,
49.9%) treated with zanamivir, with a median age of 13 years
(range, 0–96). The weekly number of antiviral treatment cases was
highly correlated with the NESID influenza activity index
(r=0.945, Figure 1) throughout the study period, indicating that
the antiviral dispensation records in the pharmacy claim database
effectively represented the national trend in influenza antiviral
treatment.
Effect of risk minimization actions on antiviral
dispensations and media coverage
Several actions in response to safety concerns of oseltamivir and
zanamivir in Japan were taken by the regulatory body and
academic societies after multiple cases of fatal falls in teenagers
were reported in February 2007 (Table S1). Oseltamivir
dispensing to children aged 10–19 years during the period from
November 2006 to March 2007, that is, before the March 2007
regulatory actions, accounted for 20.9% of the total (Table 1).
Coverage of oseltamivir in major newspapers during this period
mainly concerned the association of accidental falls with
oseltamivir use, with the intensity of reportage peaking in the
month of the regulatory advisory, issued on March 20, 2007
(Figure 2). In fiscal year 2007, the number of oseltamivir-dispensed
cases was reduced to 60.1% across ages compared with the levels
in fiscal year 2006, and dispensation to children aged 10–19 years
accounted for only 2.3% of the total (p=0.000, vs. fiscal year
2006). On comparison of the 2006/2007 and 2008/2009 seasons,
which had comparable influenza activities (Figure 1), the total
number of oseltamivir dispensations in fiscal year 2008 was almost
equal to that in fiscal year 2006 (110.4%). However, the
dispensation in children aged 10–19 years decreased to 20.4% of
the fiscal year 2006 level, corresponding to 3.9% of the total in
fiscal year 2008 (p=0.000, vs. 2006). In contrast, dispensation of
zanamivir increased approximately 8.8-fold in fiscal year 2008,
including a proportional increase in children aged 10–19 years
(855%). Yearly zanamivir dispensation to children aged 10-19
years accounted for around 45% of total dispensing throughout
the study period (Table 1, p=0.407 and 0.297 for fiscal years 2007
and 2008, vs. fiscal year 2006). Most media coverage on antivirals
during fiscal year 2008 was related to preparations, such as
national stock piling, for pandemic influenza.
Spontaneous adverse reaction reporting and dispensing
trends
Suspected adverse reactions reported for oseltamivir and
zanamivir throughout the study period were predominately
psychiatric disorders, including abnormal behavior (Figure 3).
The largest number of spontaneous case reports associated with
oseltamivir occurred in fiscal year 2007, for all categories of the
relevant event terms and classes, including eight cases of death and
two of falls. This occurred despite that year being documented as
having the lowest annual number of dispensations, indicating a
high possibility that the preceding March 2007 regulatory advisory
stimulated reporting of abnormal behavior associated with
oseltamivir in fiscal year 2007 (Table 1, Figure 3A).
In fiscal year 2008, overall spontaneous reporting associated
with oseltamivir decreased to below that in fiscal year 2006,
whereas total dispensing increased up to the level of fiscal year
2006. The number of case reports of abnormal behavior in
children aged 10-19 years decreased from 24 in fiscal year 2006 to
9 in fiscal year 2008 in parallel with the reduction in dispensation
(Table 2). However, this decrease in abnormal behavior reports
was offset by new cases arising in children aged less than 10 years
(from 12 in fiscal year 2006 to 28 in fiscal year 2008) in parallel
with increased dispensation to this age group in fiscal year 2008.
Thus, the total number of abnormal behavior reports remained
steady, from 44 in fiscal year 2006 to 42 in fiscal year 2008. No
cases of death or falls were reported for oseltamivir in fiscal year
2008.
Further, to examine changes in abnormal behavior reporting for
oseltamivir before and after the March 2007 regulatory advisory,
the 2006/2007 and 2008/2009 seasons, which had comparable
influenza activities and may therefore have been less affected by
stimulated reporting, were compared. No significant differences
were noted between fiscal years 2006 and 2008 in the reporting
Figure 1. Correlation between antiviral dispensation at community pharmacies and sentinel reporting of influenza activities in
Japan. NESID, the National Epidemiological Surveillance of Infectious Diseases.
doi:10.1371/journal.pone.0028483.g001
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oseltamivir dispensations in children aged less than 10 years and
10-19 years (Table 2).
With regard to zanamivir, in contrast, increases in the number
of spontaneous case reports for total adverse reactions (32 to 344
cases), nervous system disorders (9 to 66 cases), and psychiatric
disorders (14 to 210 cases), including several with abnormal
behavior (11 to 114 cases), were nearly proportional to the increase
in yearly dispensations between fiscal years 2006 and 2008
(Figure 3B). Only two deaths and one fall were reported for
zanamivir in fiscal year 2008. In both age groups of children (aged
less than 10 years and aged 10–19 years), the numbers of
abnormal behavior reports increased in parallel with increased
zanamivir dispensation between fiscal years 2006 and 2008
(Table 2). No significant differences were noted between fiscal
years 2006 and 2008 in the indices of reporting trends of abnormal
behaviors adjusted for the number of zanamivir dispensations in
both age groups, although these reporting indices for zanamivir
were consistently higher than those for oseltamivir.
Discussion
In this retrospective review of pharmacy dispensation records
and spontaneous adverse reaction reporting, we evaluated the
effectiveness of actions taken in response to concerns about
oseltamivir-associated risk of abnormal behavior by the regulatory
authority and the influence of mass media publicity in Japan. The
March 2007 DDL and subsequent package insert revision for
oseltamivir advising against use in children aged 10–19 years
effectively changed prescribing practices in Japan, causing a
drastic, significant reduction in oseltamivir prescriptions in this age
group and a substantial increase in total prescriptions of
zanamivir. Reporting of abnormal behaviors associated with
oseltamivir use was greatest in fiscal year 2007, partly because of
Table 1. Yearly dispensation of antiviral agents by age groups at community pharmacies in Japan.
Oseltamivir Zanamivir
Age group FY2006 (%){ FY2007 (%) FY2008 (%) FY2006 (%){ FY2007 (%) FY2008 (%)
0-9 10,039 (34.9) 7,471 (43.3) 15,702 (49.5) 383 (21.8) 740 (23.6) 3,501 (22.6)
10-19 5,991 (20.9) 389 (2.3) 1,221 (3.9) 822 (46.7) 1,507 (48.0) 7,032 (45.4)
20-29 3,401 (11.8) 2,705 (15.7) 4,136 (13.0) 174 (9.9) 316 (10.1) 1,291 (8.3)
30-39 3,732 (13.0) 3,230 (18.7) 4,729 (14.9) 180 (10.2) 289 (9.2) 1,713 (11.1)
40-49 2,421 (8.4) 1,791 (10.4) 3,031 (9.6) 96 (5.5) 161 (5.1) 1, 083 (7.0)
50-59 1,548 (5.4) 942 (5.5) 1,488 (4.7) 62 (3.5) 70 (2.2) 446 (2.9)
60- 1,592 (5.5) 732 (4.2) 1,404 (4.4) 42 (2.4) 59 (1.9) 415 (2.7)
Total 28,724 17,260 31,711 1,759 3,142 15,481
FY, fiscal year.
Values represent number of cases.
{Dispensations during each fiscal year represent the number of dispensations calculated from pharmacy dispensation records for a period starting on April 1 and ending
on the following March 31, except for fiscal year 2006 calculated from records between November 1, 2006, and March 31, 2007, due to limited data availability of
pharmacy records.
doi:10.1371/journal.pone.0028483.t001
Figure 2. Antiviral dispensation at community pharmacies, related regulatory actions and media publicity in Japan. Open boxes at
the top of each bar indicate the amount of dispensations to children aged 10–19 years. MHLW, the Ministry of Health, Welfare and Labour; DDL, Dear
doctor letter; PI, package insert.
doi:10.1371/journal.pone.0028483.g002
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coverage. Given that the decreases in the use of and abnormal
behavior reports for oseltamivir in children aged 10–19 years in
fiscal year 2008 were not reflected in the total number of abnormal
behavior cases reported in that year, the regulatory actions
targeting this age group appear to have been inappropriate in risk
minimization for the entire treatment population. In contrast, we
found that the number of zanamivir-associated case reports of
neuropsychiatric disorders increased in proportion to the yearly
increase in use. These findings will be valuable in reviewing the
effectiveness and validity of current differential safety strategies for
oseltamivir and zanamivir.
In Japan, nearly all patients with rapid antigen testing-
confirmed influenza are prescribed antiviral medications, includ-
ing oseltamivir and zanamivir [19], and a high correlation was
reported between the total number of weekly pharmacy
dispensations of oseltamivir and zanamivir and the number of
cases reported to the sentinel influenza surveillance system [20].
Figure 3. Adverse reactions reported for oseltamivir and zanamivir and antiviral dispensations. A. Oseltamivir, B. Zanamivir Single
quotation denotes individual Lower Level Term of the MedDRA coding system, although no quotation indicates System Organ Class. FY, fiscal year
starting on April 1 and ending on the following March 31. *The first bar for dispensation during fiscal year 2006 represents the number of
dispensations calculated from pharmacy dispensation records between November 1, 2006, and March 31, 2007, due to limited data availability in the
pharmacy claim database.
doi:10.1371/journal.pone.0028483.g003
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influenza activity in the present study indicate the validity of
pharmacy antiviral dispensation records as a national index for
trends in influenza medication in Japan.
We assessed the significant, combined effects of regulatory
actions, academic recommendations, and mass media publicity on
changes in the prescribing practice of oseltamivir and zanamivir.
Children aged 10-19 years accounted for a considerable portion of
all influenza patients during the study period (25.6% in the 2006/
07 season, 16.2% in the 2007/08 season, and 22.2% in the 2008/
09 season) [15]. The significant decreases in oseltamivir prescrib-
ing to children aged 10-19 years after the 2007 DDL therefore
evidenced good compliance with the regulatory actions; and the
subsequent increase in the amount of zanamivir prescriptions in
the 2008/09 season appears to have resulted from a risk-averse
attitude of selecting the alternative, as suggested by a questionnaire
survey of Japanese physicians [21]. Safety concerns about
oseltamivir received wide and continuous coverage on the Internet
and in the mass media prior to the 2007 regulatory actions,
whereas zanamivir received little attention [19]. This and other
adverse publicity about oseltamivir likely spurred strong changes
in the prescribing behavior of practitioners, probably through
heightening of public and physician sensitivity to oseltamivir risk
prior to the 2007 regulatory actions. Thus, risk communication
through the mass media appears to significantly influence public
response to a regulatory action [22].
Although annual dispensation of oseltamivir decreased in fiscal
year 2007, the number of spontaneous adverse reaction reports
associated with its use was disproportionally high. At least some of
these would have been due to the carryover of spontaneous case
reports that were not reported at the time of occurrence in the
preceding year; in fact, the domestic fiscal year 2007 Periodic
Safety Reports on oseltamivir covering April 2007 to March 2008,
submitted by the marketing authorization holder, listed many
spontaneous adverse reaction case reports with onset dates prior to
the March 2007 regulatory actions, which were received by the
marketing authorization holder after April 2007 [23]. The
spontaneous reporting on oseltamivir use in fiscal year 2007
should therefore be regarded as having been inflated by a number
of reports with onset dates received in previous years, owing to the
so-called ‘‘notoriety bias’’ resulting from the 2007 regulatory
actions and intense adverse publicity [24].
The fact that overall spontaneous reporting on oseltamivir
adverse reaction cases decreased in fiscal year 2008 indicates that
the 2007 regulatory actions were likely successful in reducing the
drug-associated events. The lack of reported deaths and falls in
fiscal year 2008 might be ascribed to social penetration of the
2007 MHLW caution on the necessity of monitoring children
with influenza within households. Nevertheless, the observed
change in the total number of case reports of abnormal behavior
in all oseltamivir users between fiscal years 2006 and 2008 was
markedly smaller than that expected from the decrease in
dispensing in children aged 10-19 years. In fact, the number of
abnormal behavior reports in this age group in fiscal year 2008
was less than half that in fiscal year 2006. This decrease was,
however, supplemented by an increased number of abnormal
behavior reports in those aged less than ten years, implying that
younger children are also at risk. The observed number of
abnormal behavior cases reported in children aged less than 10
years was not negligible, which is consistent with the finding that
influenza-associated encephalitis was mainly reported among
younger children [25]. The oseltamivir reporting trend of
abnormal behavior in children aged less than 10 years, adjusted
for pharmacy dispensations, was smaller than that for children
aged 10–19 years, which may be explained by either a true age
effect on abnormal behavior occurrence or a potential bias
caused by probably stimulated reporting for the cases in age of
10–19 years. Since the indices of reporting trends described in
the present paper should be viewed as a biased surrogate of risk,
cautions should be taken for their interpretation. However, the
number of reports in children aged less than 10 years do not rule
out the potential risk of abnormal behavior and may also raise
the necessity of appropriate risk mitigation in this population.
Thus, the restriction of oseltamivir use in children aged 10-19
years posed by the March 2007 regulatory actions warrants
reexamination.
Table 2. Comparison of antiviral dispensation and abnormal behaviors reports between 2006/2007 and 2008/2009 seasons in
childhood patients.
Age group Variables FY2006{ FY2008 P values*
Oseltamivir 0-9 Dispensed cases 10,039 15,702
Abnormal behavior reports 12 28
Reporting trend adjusted for 1,000 dispensed case 1.20 1.78 0.244
10-19 Dispensed cases 5,991 1,221
Abnormal behavior reports 24 9
Reporting trend adjusted for 1,000 dispensed case 4.01 7.37 0.114
Zanamivir 0-9 Dispensed cases 383 3,501
Abnormal behavior reports 5 35
Reporting trend adjusted for 1,000 dispensed case 13.05 10.00 0.578
10-19 Dispensed cases 822 7,032
Abnormal behavior reports 6 78
Reporting trend adjusted for 1,000 dispensed case 7.30 11.09 0.322
FY, fiscal year.
{Fiscal year represents a period starting on April 1 and ending on March 31, although, the dispensations in fiscal year 2006 represent the numbers of dispensations
calculated from records between November 1, 2006, and March 31, 2007, due to limited data availability of pharmacy records.
*P values of chi-square tests for comparison between fiscal years.
doi:10.1371/journal.pone.0028483.t002
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that the excess risk of abnormal behaviors in the oseltamivir-
treated population may be ascribable to the underlying influenza,
but not to oseltamivir [26]. Our results indicated that the number
of abnormal behavior reports is consistently dependent on the size
of populations treated with antivirals except for the reporting for
oseltamivir in fiscal year 2007. Risk of neuropsychiatric symptoms
associated with oseltamivir use has been predominantly indicated
in case reports, but not in controlled studies and preclinical
research [1,2,3,27,28,29,30,31], except for one recently reported
questionnaire-based study in Japan [32]. This previous study
indicated a slightly elevated risk of delirium with oseltamivir use in
patients under 18 during the 2006/2007-influenza season with
marginal significance (hazard ratio: 1.51, 95% CI lower: 0.95,
upper: 2.40, p=0.084). Since its extensive use in the era of swine
flu pandemic, no further cases of fatal falls in children in
association with oseltamivir use in Japan have been reported [17].
In Japan, no strong risk minimization actions against zanamivir
have been taken. However, if oseltamivir does indeed increase risk,
the fact that the indices for yearly reporting trends of abnormal
behavior cases for zanamivir in the present study remained
constant and higher than those for oseltamivir suggests that
zanamivir-treated patients also possess an excess risk of abnormal
behavior. Given also that oseltamivir and zanamivir share a
common pharmacological target and are prescribed in the same
clinical practice, we consider that the current differential safety
strategies between these two neuraminidase inhibitors should be at
least aligned within the drug class.
Limitations
The strength of inference regarding the association between
drug exposures and adverse events is affected by several
limitations. The source of our dispensation data was community
pharmacies for outpatients with a geographically heterogeneous
distribution that was not in full agreement with that of
spontaneous adverse reaction reporting. Further, due to the lack
of joint distribution of exposures and events at the individual level,
similar to ecological studies, only weak association could be
inferred in the present study [33]. Additionally, there are multiple
inherent limitations in using spontaneous adverse reaction reports
as outcome measurements, such as under- or delayed-reporting,
diagnosis inaccuracy, lack of severity information, and inflated
reporting due to intense public attention. These might bias the
assessment of adverse-reaction reporting in relation to actual
consumption [34]. Although there was a difference in the
summary periods for dispensation for fiscal year 2006 and fiscal
years 2007 and 2008, we concluded that this would not cause a
substantial bias, because the dispensation of anti-influenza agents
is usually concentrated in the influenza on-season, with only a
relatively small portion of dispensation occurring during the
influenza off-season from April to October (Figure 2). Therefore,
the above discussion should be viewed as preliminary and tested
with other robust methodologies, such as large-scale, prospective,
controlled studies, although operational difficulties may be
expected in identifying and collecting case information, such as
rare abnormal behavior, with reliability and validity in a large-
scale observational setting.
In conclusion, we demonstrated that the 2007 regulatory actions
effectively reduced oseltamivir use in children aged 10-19 years in
the wake of intense adverse publicity. This publicity would have
also strongly influenced the spontaneous reporting of oseltamivir
cases. Despite several important limitations of our data, our
preliminary findings suggesting comparable risks among children
with influenza treated with these two neuraminidase inhibitors
appear to recommend reexamination of the current differential
safety strategies by age and agent.
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